AU614515B2 - A pharmaceutical combination for the prophylaxis and therapy of malaria - Google Patents
A pharmaceutical combination for the prophylaxis and therapy of malaria Download PDFInfo
- Publication number
- AU614515B2 AU614515B2 AU15675/88A AU1567588A AU614515B2 AU 614515 B2 AU614515 B2 AU 614515B2 AU 15675/88 A AU15675/88 A AU 15675/88A AU 1567588 A AU1567588 A AU 1567588A AU 614515 B2 AU614515 B2 AU 614515B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- arteether
- pharmaceutical combination
- dihydroartemisinine
- chloroquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000004792 malaria Diseases 0.000 title claims description 15
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 238000011321 prophylaxis Methods 0.000 title description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 35
- 229960003677 chloroquine Drugs 0.000 claims description 35
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 35
- 229960002970 artemotil Drugs 0.000 claims description 34
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims description 34
- 229960002521 artenimol Drugs 0.000 claims description 28
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 claims description 28
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 21
- 229960000611 pyrimethamine Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 9
- 229960001962 mefloquine Drugs 0.000 claims description 9
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 8
- 230000002195 synergetic effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 4
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001444 amodiaquine Drugs 0.000 claims description 4
- 229960004991 artesunate Drugs 0.000 claims description 4
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005179 primaquine Drugs 0.000 claims description 4
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 4
- 229960000948 quinine Drugs 0.000 claims description 4
- 229960004673 sulfadoxine Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950002996 floxacrine Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 31
- 229960004191 artemisinin Drugs 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 12
- 241000224017 Plasmodium berghei Species 0.000 description 11
- 239000000126 substance Substances 0.000 description 8
- 239000003430 antimalarial agent Substances 0.000 description 7
- 229940033495 antimalarials Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 229960000981 artemether Drugs 0.000 description 3
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- -1 10-0methylfloxacrine Chemical compound 0.000 description 2
- ZGJHFPBCIVRXAQ-UHFFFAOYSA-N 7-(hydroxymethyl)-2,3-dihydropyrrolizin-1-one Chemical compound C1CC(=O)C2=C(CO)C=CN21 ZGJHFPBCIVRXAQ-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001445 schizonticidal effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- AWHZKKVSUJJVNL-UHFFFAOYSA-N 7-chloro-10-hydroxy-3-[4-(trifluoromethyl)phenyl]-3,4-dihydro-2h-acridine-1,9-dione Chemical compound C1C(=O)C=2C(=O)C3=CC(Cl)=CC=C3N(O)C=2CC1C1=CC=C(C(F)(F)F)C=C1 AWHZKKVSUJJVNL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000224453 Mycoplasma coccoides Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- ILSQBBRAYMWZLQ-UHFFFAOYSA-N n-(1,3-benzothiazol-2-ylsulfanyl)-n-propan-2-ylpropan-2-amine Chemical compound C1=CC=C2SC(SN(C(C)C)C(C)C)=NC2=C1 ILSQBBRAYMWZLQ-UHFFFAOYSA-N 0.000 description 1
- 231100000706 no observed effect level Toxicity 0.000 description 1
- 229940058924 other antimalarials in atc Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873715378 DE3715378A1 (de) | 1987-05-08 | 1987-05-08 | Arzneimittelkombination zur prophylaxe und therapie von malaria |
| DE3715378 | 1987-05-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1567588A AU1567588A (en) | 1988-11-10 |
| AU614515B2 true AU614515B2 (en) | 1991-09-05 |
Family
ID=6327117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU15675/88A Ceased AU614515B2 (en) | 1987-05-08 | 1988-05-06 | A pharmaceutical combination for the prophylaxis and therapy of malaria |
Country Status (11)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916204A (en) * | 1987-07-31 | 1990-04-10 | Massachusetts Institute Of Technology | Pure polyanhydride from dicarboxylic acid and coupling agent |
| AU625071B2 (en) * | 1988-04-20 | 1992-07-02 | Merrell Dow Pharmaceuticals Inc. | N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections |
| EP0362810B1 (en) * | 1988-10-07 | 1993-05-05 | Hoechst Aktiengesellschaft | Antimalarial compositions using quinidine, artemisinine and its derivatives |
| EP0535719A3 (en) * | 1988-12-06 | 1993-04-14 | Dermatologic Research Corporation | Treatment of hemorrhoids with artemisinin and derivates |
| EP0464233A1 (en) * | 1990-07-02 | 1992-01-08 | Hoechst Aktiengesellschaft | Pharmaceutical combinations against malaria |
| SG45193A1 (en) * | 1992-02-07 | 1998-01-16 | Ciba Geigy Ag | Antimalarial synergistic compositions containing benflumetol |
| GB9622427D0 (en) * | 1996-10-28 | 1997-01-08 | Pharma Mar Sa | Antimalarial drugs |
| US6160004A (en) * | 1997-12-30 | 2000-12-12 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
| IN191696B (enrdf_load_stackoverflow) * | 1999-02-12 | 2003-12-20 | Council Scient Ind Res | |
| CN1210030C (zh) * | 2000-03-28 | 2005-07-13 | 科学与工业研究委员会 | 一种新的抗微生物组合物和其制备方法 |
| WO2002032905A1 (fr) * | 2000-10-20 | 2002-04-25 | Ajinomoto Co.,Inc. | Compositions medicamenteuses, dose et procede de traitement du paludisme |
| CN1255106C (zh) | 2003-09-26 | 2006-05-10 | 李国桥 | 复方青蒿素 |
| WO2006070393A1 (en) * | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | SYNERGISTIC COMBINATION KIT OF α,ß-ARTEETHER, SULFADOXIN AND PYMETHAMINE FOR TREATMENT OF SEVERE/MULTI-DRUG RESISTANT CEREBRAL MALARIA |
| FR2884715B1 (fr) * | 2005-04-20 | 2007-06-15 | Sanofi Aventis Sa | Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme |
| WO2007043061A1 (en) * | 2005-10-11 | 2007-04-19 | Ipca Laboratories Ltd. | Anti-malarial combination and methods of formulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3302389A (en) * | 1988-04-20 | 1989-10-26 | Merrell Dow Pharmaceuticals Inc. | N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections |
| AU4263789A (en) * | 1988-10-07 | 1990-04-12 | Hoechst Aktiengesellschaft | Antimalarial compositions and methods of treatment using quinidine, artemisinine and its derivatives |
-
1987
- 1987-01-29 IN IN26/BOM/87A patent/IN166154B/en unknown
- 1987-05-08 DE DE19873715378 patent/DE3715378A1/de not_active Withdrawn
-
1988
- 1988-05-05 EP EP88107223A patent/EP0290959A3/de not_active Withdrawn
- 1988-05-05 ZA ZA883209A patent/ZA883209B/xx unknown
- 1988-05-06 DK DK249688A patent/DK249688A/da unknown
- 1988-05-06 IL IL86302A patent/IL86302A0/xx unknown
- 1988-05-06 JP JP63109239A patent/JPS6452714A/ja active Pending
- 1988-05-06 HU HU882314A patent/HU200688B/hu not_active IP Right Cessation
- 1988-05-06 PT PT87427A patent/PT87427B/pt not_active IP Right Cessation
- 1988-05-06 AU AU15675/88A patent/AU614515B2/en not_active Ceased
- 1988-05-07 KR KR1019880005305A patent/KR880013558A/ko not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3302389A (en) * | 1988-04-20 | 1989-10-26 | Merrell Dow Pharmaceuticals Inc. | N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections |
| AU4263789A (en) * | 1988-10-07 | 1990-04-12 | Hoechst Aktiengesellschaft | Antimalarial compositions and methods of treatment using quinidine, artemisinine and its derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| HU200688B (en) | 1990-08-28 |
| ZA883209B (en) | 1988-11-08 |
| IL86302A0 (en) | 1988-11-15 |
| DK249688D0 (da) | 1988-05-06 |
| EP0290959A3 (de) | 1990-03-07 |
| JPS6452714A (en) | 1989-02-28 |
| PT87427B (pt) | 1992-09-30 |
| PT87427A (pt) | 1989-05-31 |
| DK249688A (da) | 1988-11-09 |
| AU1567588A (en) | 1988-11-10 |
| HUT47846A (en) | 1989-04-28 |
| KR880013558A (ko) | 1988-12-21 |
| IN166154B (enrdf_load_stackoverflow) | 1990-03-24 |
| DE3715378A1 (de) | 1988-11-24 |
| EP0290959A2 (de) | 1988-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5219865A (en) | Pharmaceutical combination for the prophylaxis and therapy of malaria | |
| AU614515B2 (en) | A pharmaceutical combination for the prophylaxis and therapy of malaria | |
| EP0362810B1 (en) | Antimalarial compositions using quinidine, artemisinine and its derivatives | |
| AU2006238506B2 (en) | Association between ferroquine and an artemisinine derivative for treating malaria | |
| AU642747B2 (en) | Antimalarial compositions | |
| Nontprasert et al. | Assessment of the neurotoxicity of oral dihydroartemisinin in mice | |
| JPS63310819A (ja) | 抗レトロウイルス活性をもつ糖タンパク処理抑制剤 | |
| WO2005023304A2 (en) | Antimalarial compositions and manufacturing process thereof | |
| AU2009227092B2 (en) | Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria | |
| Hien et al. | Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria | |
| WO1991012804A1 (en) | New use | |
| JP2001507672A (ja) | Ｃｉｓ―縮合シクロペンテノ―１，２，４―トリオキサン誘導体を含有する抗マラリア組成物 | |
| WO2017143964A1 (zh) | Quisinostat，一种新型的高效抗疟药物 | |
| AU625071B2 (en) | N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections | |
| US5373005A (en) | Despiramine in the treatment of drug-resistant malarial infections | |
| JPH0873355A (ja) | 抗マラリア薬耐性克服剤 | |
| JPH04230322A (ja) | 抗マラリア医薬組成物 | |
| HUP0301925A2 (hu) | Kinolinszármazékokat tartalmazó kombinált készlet malária kezelésére | |
| Song et al. | Current Treatments for Malaria 10 | |
| Ashley et al. | Management of Multiple Drug-Resistant Malaria | |
| HK1119069A (en) | Association between ferroquine and an artemisinine derivative for treating malaria | |
| HK1178440A (en) | Association between ferroquine and an artemisinine derivative for treating malaria | |
| HK1152892B (en) | Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |